William J Peppard

Summary

Affiliation: Froedtert Hospital
Country: USA

Publications

  1. ncbi Role of linezolid in the treatment of complicated skin and soft tissue infections
    William J Peppard
    Froedtert Hospital, 9200 W Wisconsin Avenue, Milwaukee, WI 53226, USA
    Expert Rev Anti Infect Ther 4:357-66. 2006
  2. ncbi Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections
    William J Peppard
    Froedtert Hospital, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA
    Curr Opin Investig Drugs 9:210-25. 2008
  3. ncbi Pharmacologic options for CNS infections caused by resistant Gram-positive organisms
    William J Peppard
    Clinical Pharmacist, Surgical Critical Care, Froedtert Hospital, 9200 West, Wisconsin Avenue, Milwaukee, WI 53226, USA
    Expert Rev Anti Infect Ther 6:83-99. 2008
  4. ncbi Linezolid for the treatment of drug-resistant infections
    David J Herrmann
    Trauma Surgical Critical Care Pharmacist, Froedtert Hospital, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA
    Expert Rev Anti Infect Ther 6:825-48. 2008

Detail Information

Publications4

  1. ncbi Role of linezolid in the treatment of complicated skin and soft tissue infections
    William J Peppard
    Froedtert Hospital, 9200 W Wisconsin Avenue, Milwaukee, WI 53226, USA
    Expert Rev Anti Infect Ther 4:357-66. 2006
    ..Currently, there are only a few new antibiotics in development with MRSA activity. The proper use of all antibiotics, including these newer agents, is increasingly important if we are to slow the evolution of microbial resistance...
  2. ncbi Iclaprim, a diaminopyrimidine dihydrofolate reductase inhibitor for the potential treatment of antibiotic-resistant staphylococcal infections
    William J Peppard
    Froedtert Hospital, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA
    Curr Opin Investig Drugs 9:210-25. 2008
    ..Phase III cSSSI clinical trials have been completed and an NDA filing process is ongoing. A phase II clinical trial for hospital-acquired pneumonia is ongoing...
  3. ncbi Pharmacologic options for CNS infections caused by resistant Gram-positive organisms
    William J Peppard
    Clinical Pharmacist, Surgical Critical Care, Froedtert Hospital, 9200 West, Wisconsin Avenue, Milwaukee, WI 53226, USA
    Expert Rev Anti Infect Ther 6:83-99. 2008
    ..Interpretations of these data are offered followed by a brief presentation of future therapies, including ortavancin, telavancin, dalbavancin, ceftobiprole and iclaprim, all of which possess potent Gram-positive activity...
  4. ncbi Linezolid for the treatment of drug-resistant infections
    David J Herrmann
    Trauma Surgical Critical Care Pharmacist, Froedtert Hospital, 9200 West Wisconsin Avenue, Milwaukee, WI 53226, USA
    Expert Rev Anti Infect Ther 6:825-48. 2008
    ....